Recent developments in multifunctional hybrid nanoparticles: Opportunities and challenges in cancer therapy

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 1, 2012, Pages 529-545

  Morales, Carolina Salvador ^a,b   Valencia, Pedro M ^a,b   Thakkar, Anjali B ^a,b   Swanson, Edward ^a,b   Langer, Robert ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Biocompatibility; Cancer; Hybrid nanoparticles

Indexed keywords

DOXORUBICIN; ELACRIDAR; LIPOSOME; METAL; NANOCARRIER; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; POLYMER; QUANTUM DOT; SILICON DIOXIDE;

ARTICLE; BIOCOMPATIBILITY; BLOOD COMPATIBILITY; CANCER THERAPY; CONTROLLED RELEASE FORMULATION; DRUG ADSORPTION; DRUG DEGRADATION; DRUG PROTEIN BINDING; DRUG STABILITY; HUMAN; HYBRID; HYDROPHOBICITY; LOADING DRUG DOSE; MOLECULAR STABILITY; NANOENCAPSULATION; PARTICLE SIZE; SINGLE DRUG DOSE; SURFACE PROPERTY; NEOPLASM; REVIEW;

HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 84860853400     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/398     Document Type: Article

References (108)

1. O. C. Farokhzad and R. Langer: Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16-20 (2009)
2. M. Ferrari: Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 5(3), 161-71 (2005)
3. M. E. Gindy and R. K. Prud'homme: Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv, 6(8), 865-78 (2009)
4. L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer and O. C. Farokhzad: Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther, 83(5), 761-9 (2008)
5. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit and R. Langer: Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2(12), 751-60 (2007)
6. O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie and R. Langer: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A, 103(16), 6315-20 (2006)
7. V. P. Torchilin: Micellar nanocarriers: pharmaceutical perspectives. Pharm Res, 24(1), 1-16 (2007)
8. V. P. Torchilin: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 4(2), 145-60 (2005)
9. J. R. Baker, Jr.: Dendrimer-based nanoparticles for cancer therapy. Hematology Am Soc Hematol Educ Program, 708-19 (2009)
10. S. R. Ji, C. Liu, B. Zhang, F. Yang, J. Xu, J. Long, C. Jin, D. L. Fu, Q. X. Ni and X. J. Yu: Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta
11. I. Brigger, C. Dubernet and P. Couvreur: Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev, 54(5), 631-51 (2002)
12. E. Tasciotti, X. Liu, R. Bhavane, K. Plant, A. D. Leonard, B. K. Price, M. M. Cheng, P. Decuzzi, J. M. Tour, F. Robertson and M. Ferrari: Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol, 3(3), 151-7 (2008)
13. X. Michalet, F. F. Pinaud, L. A. Bentolila, J. M. Tsay, S. Doose, J. J. Li, G. Sundaresan, A. M. Wu, S. S. Gambhir and S. Weiss: Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 307(5709), 538-44 (2005)
14. L. Zhang, J. M. Chan, F. X. Gu, J. W. Rhee, A. Z. Wang, A. F. Radovic-Moreno, F. Alexis, R. Langer and O. C. Farokhzad: Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano, 2(8), 1696-702 (2008)
15. H. L. Wong, R. Bendayan, A. M. Rauth and X. Y. Wu: Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci, 93(8), 1993-2008 (2004)
16. B. Dubertret, P. Skourides, D. J. Norris, V. Noireaux, A. H. Brivanlou and A. Libchaber: In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science, 298(5599), 1759-62 (2002)
17. K. Avgoustakis: Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv, 1(4), 321-33 (2004)
18. R. Weissleder, K. Kelly, E. Y. Sun, T. Shtatland and L. Josephson: Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol, 23(11), 1418-23 (2005)
19. G. von Maltzahn, T. J. Harris, J. H. Park, D. H. Min, A. J. Schmidt, M. J. Sailor and S. N. Bhatia: Nanoparticle selfassembly gated by logical proteolytic triggers. J Am Chem Soc, 129(19), 6064-5 (2007)
20. F. Gu, L. Zhang, B. A. Teply, N. Mann, A. Wang, A. F. Radovic-Moreno, R. Langer and O. C. Farokhzad: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A, 105(7), 2586-91 (2008)
21. F. Alexis, P. Basto, E. Levy-Nissenbaum, A. F. Radovic-Moreno, L. Zhang, E. Pridgen, A. Z. Wang, S. L. Marein, K. Westerhof, L. K. Molnar and O. C. Farokhzad: HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem, 3(12), 1839-43 (2008)
22. E. M. Pridgen, R. Langer and O. C. Farokhzad: Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomed, 2(5), 669-80 (2007)
23. V. Wagner, A. Dullaart, A. K. Bock and A. Zweck: The emerging nanomedicine landscape. Nat Biotechnol, 24(10), 1211-7 (2006)
24. B. Hughes: 2008 FDA drug approvals. Nature Reviews, 8(93-96) (2009)
25. M. Liong, J. Lu, M. Kovochich, T. Xia, S. G. Ruehm, A. E. Nel, F. Tamanoi and J. I. Zink: Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano, 2(5), 889-96 (2008)
26. Y. Li, N. Taulier, A.M. Rauth, and X.Y. Wu: Screening of lipid carrier and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN). Pharmaceutical Research 23, 1877-1887 (2006)
27. Z. S. Haidar, R.C. Hamdy, and M.Tabrizian: Protein release kinetics for core-shell hybrid nanoparticles based on the layer-by-layer assembly of alginate and chitosan on liposomes. Biomaterials, 29, 1207-1215 (2008)
28. H. L. Wong, R. Bendayan, A.M. Rauth, and X.Y. Wu: Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. Journal of controlled release, 116, 275-284 (2006)
29. R. Guo, R. Li, X. Li, L. Zhang, X. Jiang, and B. Liu: Dual-functional alginic acid hybrid nanospheres for cell imaging and drug delivery. Small, 5, 709-717 (2009)
30. X. Zhang, Y. Yang, J. Tian and H. Zhao: Vesicles fabricated by hybrid nanoparticles. Chem Commun (Camb)(25), 3807-9 (2009)
31. W. T. Al-Jamal, K.T. Al-Jamal, B. Tian, L.Lacerda, P.H. Bomans, P.M. Frederik, and K. Kostarelos: Lipid-Quantum dot bilayer vesicles enhance tumor cell uptake and retention in vitro and in vivo. ACS NANO, 2, 408-418 (2008)
32. W. T. Al-Jamal, K.T. Al-Jamal, P.H. Bomans, P.M. Frederik, and K. Kostarelos: Functionalized-quantumdot-liposome hybrids as multimodal nanoparticles for cancer Small, 4, 1406-1415 (2008)
33. W. T. Al-Jamal, K.T. Al-Jamal, A. Cakebread, J.M. Halket, and K. Kostarelos: Blood circulation and tissue biodistribution of lipid-quantum dot (L-QD) hybrid vesicles intravenously administered in mice. Bioconjugate, 20, 1696-702 (2009)
34. S. A. Miller, E.D. Hong, and D. Wright: Rapid and efficient enzyme encapsulation in a dendrimer silica nanocomposite. Macromol Biosci, 6, 839-845 (2006)
35. J. M. Rosenholm, A. Meinander, E. Peuhu, R. Niemi, and J.E. Eriksson: Targeting of porous hybrid silica nanoparticles for cancer cells. ACS NANO, 3, 197-206 (2009)
36. A. Tan, S. Simovic, A.K. Davey, T. Rades, and C.A Prestidge: Silica-lipid hybrid (SLH) microcapsules: A novel oral delivery system for poorly soluble drugs. Journal of controlled release, 134, 62-70 (2009)
37. Y. Li, H. L. Wong, A. J. Shuhendler, A. M. Rauth and X. Y. Wu: Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Control Release, 128(1), 60-70 (2008)
38. Y. Kobayashi, H. Katakami, E. Mine, D. Nagao, M. Konno and L. M. Liz-Marzan: Silica coating of silver nanoparticles using a modified Stober method. J Colloid Interface Sci, 283(2), 392-6 (2005)
39. D. Teijeiro-Osorio, C. Remunan-Lopez and M. J. Alonso: New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules, 10(2), 243-9 (2009)
40. I. De Miguel, L. Imbertie, V. Rieumajou, M. Major, R. Kravtzoff and D. Betbeder: Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers. Pharm Res, 17(7), 817-24 (2000)
41. J. Thevenot, A. L. Troutier, L. David, T. Delair and C. Ladaviere: Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Biomacromolecules, 8(11), 3651-60 (2007)
42. H. L. Wong, A. M. Rauth, R. Bendayan, J. L. Manias, M. Ramaswamy, Z. Liu, S. Z. Erhan and X. Y. Wu: A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res, 23(7), 1574-85 (2006)
43. P. M. Valencia, P. A. Basto, L. Zhang, M. Rhee, R. Langer, O. C. Farokhzad and R. Karnik: Single-Step Assembly of Homogenous Lipid-Polymeric and Lipid-Quantum Dot Nanoparticles Enabled by Microfluidic Rapid Mixing. ACS Nano
44. M. E. Gindy, A. Z. Panagiotopoulos and R. K. Prud'homme: Composite block copolymer stabilized nanoparticles: simultaneous encapsulation of organic actives and inorganic nanostructures. Langmuir, 24(1), 83-90 (2008)
45. W. Stober, A. Fink and E. Bohn: Controlled Growth of Monodisperse Silica Spheres in Micron Size Range. Journal of Colloid and Interface Science, 26(1), 62-& (1968)
46. J. H. Park, G. von Maltzahn, E. Ruoslahti, S. N. Bhatia and M. J. Sailor: Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed Engl, 47(38), 7284-8 (2008)
47. S. T. Stern and S. E. McNeil: Nanotechnology safety concerns revisited. Toxicol Sci, 101(1), 4-21 (2008)
48. J. B. Hall, M. A. Dobrovolskaia, A. K. Patri and S. E. McNeil: Characterization of nanoparticles for therapeutics. Nanomed, 2(6), 789-803 (2007)
49. J. M. Chan, L. Zhang, K.P. Yuet, G. Liao, J.M. Rhee, R. Langer, and O.C. Farokhzad: PLGA-Lecithin-PEG coreshell nanoparticles for controlled drug delivery. Biomaterials, 30, 1627-1634 (2009)
50. S. M. Moghimi, A. C. Hunter and J. C. Murray: Longcirculating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53(2), 283-318 (2001)
51. P. Papaphilippou, L. Loizou, N. C. Popa, A. Han, L. Vekas, A. Odysseos and T. Krasia-Christoforou: Superparamagnetic hybrid micelles, based on iron oxide nanoparticles and well-defined diblock copolymers possessing beta-ketoester functionalities. Biomacromolecules, 10(9), 2662-71 (2009)
52. G. Kalyuzhny, and R.W. Murray Ligand effects on optical properties of CdSe nanocrystals. J Phys Chem B, 109, 7012-7021 (2005)
53. P. M. Bullen C.: The effects of chemisorption on the luminescence of CdSe quantum dots. Langmuir, 22, 3007-3013 (2006)
54. A. Komoto, S. Maenosomo, and Y. Yamaguchi: Oscillating fluorescence in an unstable colloidal dispersion of CdSe/ZnS core/shell quantum dots. Langmuir, 20, 8916-8923 (2004)
55. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin and R. Langer: Biodegradable long-circulating polymeric nanospheres. Science, 263(5153), 1600-3 (1994)
56. R. Gref, Y. Minamitake, M. T. Peracchia, A. Domb, V. Trubetskoy, V. Torchilin and R. Langer: Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration. Pharm Biotechnol, 10, 167-98 (1997)
57. C. Womersley, P.S. Uster, A.S. Rudolph, and J.H. Crowe Inhibition of dehydration-induced fusion between liposomal membranes by carbohydrates as measured by fluorescence energy transfer. Cryobiology, 23, 245-255 (1986)
58. T. Ishihara, M. Goto, H. Kanazawa, M. Higaki, and Y. Mizushima: Efficient entrapment of poorly water-soluble pharmaceuticals in hybrid nanoparticles. Journal of pharmaceuticals sciences, 98, 2357-2363 (2009)
59. H. L. Wong, R. Bendayan, A.M. Rauth, H.Y. Xue, K. Babakhanian, and X.Y. Wu: A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Pharmacology and experimental therapeutics, 317, 1372-1381 (2006)
60. Y. Li, H.L Wong, A.J. Shuhendler, A.M. Rauth, and X.Y. Wu Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. Journal of controlled release, 128, 60-70 (2008)
61. O. C. Farokhzad: Nanotechnology for drug delivery: the perfect partnership. Expert Opin Drug Deliv, 5(9), 927-9 (2008)
62. W. T. Al-Jamal, K.T.Al-Jamal, B. Tian, A. Cakebread, J.M.Halket, and K. Kostarelos: Tumor targeting of functionalized quantum dot-liposome hybrids by intravenous administration Molecular pharmaceuticals, 6, 520-530 (2009)
63. K. G.S: Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier Syst, 20, 357-403 (2003)
64. T. V.P: Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res, 24, 1-16 (2007)
65. K. S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, and W.E.Rudzinski: Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 70, 1-20 (2001)
66. P. Couvreur, B. Kante, M. Roland, and P. Speiser: Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J Pharm Sci, 68, 1521-1523 (1979)
67. M. Egea, F. Gamisani, J. Valero, M.E. Garcia, and M.L. Garcia Entrapment of cisplatin into biodegradable polyalkylcyanoacrylate nanoparticle. Farmaco, 49, 211-217 (1994)
68. A. Pal, K. Esumi, and T. Pal: Preparation of nanosized gold particles in a biopolymer using UV photoactivation. J colloid interface sci, 288, 396-401 (2005)
69. G. Montalvo, and A. Khan: Self-assembly of mixed ionic and zwitterionic amphiphiles: Associative and dissociative interactions between lamellar phases. Langmuir, 18, 8350-8357 (2002)
70. X. Zhang, Y. Yang, J. Tian, and H. Zhao: Vesicles fabricated by hybrid nanoparticles. Chem Commun, 3807-3809 (2009)
71. B. K. Johnson and R. K. Prud'homme: Mechanism for rapid self-assembly of block copolymer nanoparticles. Phys Rev Lett, 91(11), 118302 (2003)
72. M. S. Hasan A.S., A. Lamprecht, F. E. Ghazouani, A. Sapin, M. Hoffman, P. Maincent, and N. Ubrich Effect of the microencapsulation of nanoparticles on the reduction of burst release. International Journal of Pharmaceutics, 344, 53-61 (2007)
73. I. F. Tannock: Tumor physiology and drug resistance. Cancer Metastasis Rev, 20(1-2), 123-32 (2001)
74. L. S. Jabr-Milane, L.E. Van Vlerken, S. Yadav, and M.M. Amiji: Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev, 34, 592-602 (2008)
75. I. F. Tannock: Tumor physiology and drug resistance Cancer Metastasis Rev, 20, 123-32 (2001)
76. S. Yadav, L.E. Van Vlerken, S.R. Little, and M.M. Amiji: Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticles formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol, 63, 711-722 (2009)
77. L. E. Babcock: New Permian conulariids from Devon Island, Canada. Journal of Paleontology, 62(4), 615 (1988)
78. L. Fenart, A. Casanova, B. Dehouck, C. Duhem, S. Slupek, R. Cecchelli, and D. Betbeder Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther, 291, 1071-1022 (1999)
79. D. V. Thierry A.R., S.S. Coughlin, J.A.Belli, A. Dritschilo, and A. Rahman: Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J, 7, 572-579 (1993)
80. R. H. Muller, K. Mader, and S. Gohla: Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50, 161-77 (2000)
81. D. C. Soma CE, Barratt G, Nemati F, Appel M, Benita S, Couvreur P: Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res, 16(11), 1710-1716 (1999)
82. Y. Romsicki, and F.J. Sharom: The membrane lipid environment modulates drug interactions with the Pglycoprotein multidrug transporter. Biochemistry, 38, 6887-6896 (1999)
83. L. Serpe, M.G. Catalano, R. Cavalli, E. Ugazio, O.Bosco, R. Canaparo, E. Muntoni, R. Frairia, M.R. Gasco, M. Eandi, and G.P. Zara: Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm, 58, 673-80 (2004)
84. R. D. Muller RH, Runge S, Schulze-Foster k, Mehnert W, : Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res, 14(4), 458-462 (1997)
85. X. Dong, C.A. Mattingly, M.T. Tseng, M.J. Cho, Y. Liu, V.R. Adams, and R.J. Mumper: Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res, 69, 3918-3926 (2009)
86. G. C. Wishart, D. Bissett, J. Paul, D. Jodrell, A. Harnett, T. Habeshaw, D.J. Kerr, M.A. Macham, M. Soukop, R.C. Leonard, and et al.: Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol, 12, 1771-1777 (1994)
87. A. S. Planting, P. Sonneveld, A.Van der Gaast, A. Sparreboom, M.E. Van der Burg, G.P. Luyten, K. De Leeuw, M. De Boer-Dennert, P.S. Wissel, R.C. Jewell, E.M. Paul, N.B. Purvis, and J. Verweij: A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol, 55, 91-99 (2005)
88. M. Saad, O.B. Garbuzenko, and T. Minko: Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine, 3, 761-76 (2008)
89. S. Sengupta, D. Eavarone, I. Capila, G. Zhao, N. Watson, T. Kiziltepe, and R. Sasisekharan: Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436, 568-572 (2005)
90. D. F. Williams: The willians dictionary of biomaterials (1999)
91. C. Salvador-Morales, L. Zhang, R. Langer, and O.C. Farokhzad: Immunocompatibility properties of lipidpolymer hybrid nanoparticles with heterogenous surface functional groups. Biomaterials, 30, 2231-2240 (2009)
92. J. Szebeni, C.R. Alving, L.Rosivall, R.Bunger, L.Baranyi, P. Bedocs, M.Toth, and Y. Barenholz: Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. Journal of liposome research, 17, 107-117 (2007)
93. J. SZebeni, F.M. Muggia, and C.R. Alving: Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. Journal of the national cancer institute, 90, 300-306 (1998)
94. J. Szebeni, J.L. Fontana, N.M. Wassef, P.D. Mongan, D.S. Morse, D.E. Dobbins, G.L. Stahl, R. Bunger, and C.R. Alving: Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation, 99, 2302-2309 (2008)
95. J. Szebeni, L.Baranyi, S. Savay, J. Milosevits, R. Bunger, P. Laverman, J.M. Metselaar, G.Storm, A. Chanan-Khan, L.Liebes, F.M. Muggia, R.Cohen, Y. Barenholz, and C.R. Alving Role of complement activation in hypersensitivity reactions to doxil and hynic peg liposomes: experimental and clinical studies. Journal of liposome research, 12, 165-172 (2002)
96. R. B. Sim, and S.A. Tsiftsoglou: Proteases of the complement system. Biochem Soc Trans, 32, 21-27 (2004)
97. J. Andersson, E.K. Nilsson, R. Larsson, U.R. Nilsson, and B. Nilsson: C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunology 168, 5786-5791 (2002)
98. M. A. Dobrovolskaia, A.K. Patri, J. Zheng, J.D. Clogston, N. Ayud, P. Aggarwal, B.W. Neun, J.B. Hall, and S.E. McNeil: Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine, 5, 106-117 (2009)
99. M. Hulander, J. Hong, M. Andersson, F. Gervén, M. Ohrlander, P. Tengvall, and H. Elwing: Blood Interactions with Noble Metals: Coagulation and Immune Complement Activation. ACS Applied Materials and interfaces, 1, 1053-1062 (2009)
100. J. Y. Shim, and V.K. Gupta: Reversible aggregation of gold nanoparticles induced by pH dependent conformational transitions of a self-assembled polypeptide. Journal of Colloid and Interface Sciences, 316, 977-983 (2007)
101. Archaeos Projects: Preliminary Site Report of the Oriental Institute of the University of Vienna and Archaeos: Excavation Project at Tell Arbid, Sector D. In: Archaeos, Inc., New York (1999)
102. S. P. Hudson, R.F. Padera, R. Langer, and D.S. Kohane: Biocompatibility of mesoporous materials. Biomaterials, 29, 4045-4055 (2008)
103. K.Whaely: Methods in Complement for Clinical Immunologists (1985)
104. H. S. Choi, L. Wenhao, P. Misra, E. Tanaka, J.P. Zimmer, and B. Ipe:Renal clearance of quantum dots. Nature Biotechnology, 25, 1165-1170 (2007)
105. S. D. Bruck: Interactions of synthetic and natural surfaces with blood in the physiological environment. J Biomed Mater Res, 11(1), 1-21 (1977)
106. T. A. Horbett: Principles underlying the role of adsorbed plasma proteins in blood interactions with foreign materials. Cardiovasc Pathol 2, 137S-148S (1993)
107. S. E. McNeil: Nanoparticle therapeutics: A personal perspective. WIREs Nanomed. Nanobiotechnol 1, 264-271 (2009)
108. S. P. Hudson, J. Cooney, and E. Magner: Proteins in mesoporous silicates. Angew Chem Int Ed, 47, 8582-8594 (2008)